ageforce bpc 157 patch BPC-157 – Research Peptide Peptide Recovery Patch - Transdermal

Studies tracking radiolabeled peptide demonstrate metabolism primarily in plasma, with resulting amino acids entering normal metabolic pathways

The first agent in this class was approved in 2005 for type 2 diabetes, and ongoing studies continue to look at their broader applications, long-term benefits and safety profile

Pellegrino M, Mancini F, Luc R, Coletti A, Giacch N, Manni I, et al

Seek urgent medical attention if you experience severe abdominal pain, persistent vomiting, signs of an allergic reaction, chest pain, or dehydration, and inform the clinician of the substance used

BPC-157 is often chosen for its more targeted reputation, while TB-500 is chosen for its broader repair reputation